TScan Therapeutics (TCRX) Cash & Equivalents (2020 - 2026)

TScan Therapeutics (TCRX) has reported Cash & Equivalents for 7 consecutive years, with $128.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 16.9% year-over-year to $128.1 million; the TTM figure through Mar 2026 stood at $128.1 million (down 16.9% YoY), while the FY2025 annual figure was $152.4 million, down 14.71% from the prior year.
• Cash & Equivalents slipped to $128.1 million in Q1 2026 per TCRX's latest filing, from $152.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $242.2 million in Q2 2024 and bottomed at $95.6 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $152.0 million across 5 years, with a median of $140.8 million in 2022.
• On a YoY basis, Cash & Equivalents climbed as much as 66.27% in 2023 and fell as far as 32.11% in 2023.
• TScan Therapeutics' Cash & Equivalents stood at $120.0 million in 2022, then gained by 11.11% to $133.4 million in 2023, then jumped by 33.99% to $178.7 million in 2024, then decreased by 14.71% to $152.4 million in 2025, then declined by 15.98% to $128.1 million in 2026.
• Business Quant data shows TCRX's Cash & Equivalents at $128.1 million in Q1 2026, $152.4 million in Q4 2025, and $169.5 million in Q3 2025.